REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 154 filers reported holding REATA PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is 0.63 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $14,682 | +11.4% | 144 | -0.7% | 0.00% | 0.0% |
| Q1 2023 | $13,183 | +339.3% | 145 | +83.5% | 0.00% | – |
| Q4 2022 | $3,001 | +50.0% | 79 | +8.2% | 0.00% | – |
| Q3 2022 | $2,000 | +100.0% | 73 | +49.0% | 0.00% | – |
| Q2 2022 | $1,000 | 0.0% | 49 | +96.0% | 0.00% | – |
| Q1 2022 | $1,000 | -66.7% | 25 | -3.8% | 0.00% | -100.0% |
| Q3 2021 | $3,000 | -25.0% | 26 | -16.1% | 0.00% | 0.0% |
| Q2 2021 | $4,000 | -20.0% | 31 | -36.7% | 0.00% | 0.0% |
| Q1 2021 | $5,000 | -16.7% | 49 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $6,000 | +200.0% | 49 | +145.0% | 0.00% | 0.0% |
| Q3 2020 | $2,000 | -93.8% | 20 | -95.0% | 0.00% | -91.7% |
| Q3 2019 | $32,000 | – | 400 | – | 0.01% | – |
| Q2 2019 | $0 | -100.0% | 0 | -100.0% | 0.00% | -100.0% |
| Q1 2019 | $42,000 | 0.0% | 500 | -33.3% | 0.02% | -19.0% |
| Q4 2018 | $42,000 | – | 750 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CPMG Inc | 2,896,901 | $291,457,000 | 32.14% |
| PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE | 46,646 | $4,693,000 | 5.31% |
| Ikarian Capital, LLC | 471,400 | $47,423,000 | 3.34% |
| Duquesne Family Office | 695,033 | $69,927,000 | 2.27% |
| Camber Capital Management LP | 685,000 | $68,918,000 | 2.12% |
| LBJ Family Wealth Advisors, Ltd. | 30,359 | $3,054,000 | 1.82% |
| MADDEN SECURITIES Corp | 33,127 | $3,333,000 | 1.80% |
| Biondo Investment Advisors, LLC | 104,120 | $10,475,000 | 1.80% |
| Tolleson Wealth Management, Inc. | 60,750 | $6,112,000 | 1.73% |
| Keel Point, LLC | 97,074 | $9,767,000 | 1.26% |